Evoke Pharma, Inc.
12671 High Bluff Drive
Suite 200
San Diego
California
92130
United States
Tel: 858-967-5454
Website: http://www.evokepharma.com/
172 articles about Evoke Pharma, Inc.
-
Evoke Pharma Reports Third Quarter 2019 Financial ResultsGimoti NDA resubmission on track for fourth quarter 2019
11/7/2019
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2019.
-
The CRL is not totally unexpected, given that last month the company received a multi-disciplinary review (DR) letter from the FDA regarding its New Drug Application.
-
There are three companies looking for decisions by the U.S. Food and Drug Administration (FDA) this week. All three drugs are either resubmissions or have had to deal with various problems related to manufacturing or incomplete data. Here’s a look.
-
Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti
2/15/2018
The Company has filed new patent applications related to the discovery.
-
Evoke Pharma Reports Third Quarter 2017 Results and Highlights
11/15/2017
For the third quarter of 2017, net loss was approximately $5.2 million, or $(0.34) per share, compared to a net loss of approximately $3.0 million, or $(0.29) per share, for the three-month period ended September 30, 2016.
-
Evoke Pharma Signs Commercial Agreement with Thermo Fisher Scientific
11/9/2017
Under the five-year agreement, Thermo Fisher will manufacture Gimoti for Evoke’s potential commercial efforts.
-
Evoke Pharma Schedules Conference Call and Webcast for Third Quarter 2017 Financial Results
11/7/2017
Evoke will hold a conference call on Tuesday, November 14, 2017 at 4:30 pm ET to discuss the results.
-
Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti
10/27/2017
Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti.
-
Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti
10/23/2017
505(b)(2) NDA on track for FDA submission in Q1 2018.
-
Evoke Pharma Completes Dosing For Gimoti Comparative Exposure Pharmacokinetic Study
9/12/2017
-
Evoke Pharma Reports Second Quarter 2017 Results And Highlights
8/15/2017
-
Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study For Gimoti
8/14/2017
-
Evoke Pharma Schedules Conference Call And Webcast For Second Quarter 2017 Financial Results
8/7/2017
-
Evoke Pharma Enters Agreement With Rho To Submit NDA For Gimoti
5/31/2017
-
Evoke Pharma Reports First Quarter 2017 Results
5/16/2017
-
Evoke Pharma Presents Gimoti Efficacy And Safety Data From Phase III Trial As Late Breaker At Digestive Disease Week 2017
5/10/2017
-
Evoke Pharma Schedules Conference Call And Webcast For First Quarter 2017 Financial Results
5/1/2017
-
Evoke Pharma Announces Collaboration With Spaulding Clinical Research h For The Gimoti Comparative Exposure Pharmacokinetic Trial
4/18/2017
-
Evoke Pharma Receives Positive NDA Submission Guidance From U.S. FDA For Gimoti
12/19/2016
-
Evoke Pharma Schedules Webcast and Conference Call For Third Quarter 2016 Financial Results
11/1/2016